defa14a
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o Definitive Proxy Statement
þ Definitive Additional Materials
o Soliciting Material Pursuant to §240.14a-12
Aastrom Biosciences, Inc.
(Name of Registrant as Specified in Its Charter)
Payment of filing fee (Check the appropriate box):
þ |
|
No fee required. |
|
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which filing fee is calculated and
state how it was determined): |
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
(5) |
|
Total fee paid: |
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11 (a) (2) and
identify the filing for which the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the Form or Schedule and the date of its filing.
|
(1) |
|
Amount previously paid: |
|
|
(2) |
|
Form, Schedule or Registration No.: |
|
|
(3) |
|
Filing Party: |
|
|
(4) |
|
Date Filed: |
[Aastrom Logo]
FOR IMMEDIATE RELEASE
|
|
|
|
|
CONTACTS:
|
|
Kris M. Maly or Kimberli OMeara
Investor Relations Department
Aastrom Biosciences, Inc.
Phone: (734) 930-5777
|
|
Kevin McGrath
Cameron & Associates (Investors)
Phone: (212) 245-4577 |
INSTITUTIONAL SHAREHOLDER SERVICES, INC. RECOMMENDS
AASTROM SHAREHOLDERS VOTE FOR FISCAL YEAR 2008
GOOD CORPORATE GOVERNANCE PROXY PROPOSALS
Aastrom Commended for Submitting Proposals in Best Interest of Shareholders
Ann Arbor, Michigan, September 29, 2008 Aastrom Biosciences, Inc. (Nasdaq: ASTM), a leading
regenerative medicine company, today announced that Institutional Shareholder Services, Inc. (ISS),
a wholly-owned subsidiary of RiskMetrics Group, Inc., one of the nations leading proxy advisory
firms, has recommended that Aastrom shareholders vote FOR both the declassification of the Board
of Directors which, if passed, will result in the annual election of all Directors, and the
elimination of the supermajority vote requirement at the Annual Meeting of Shareholders scheduled
for October 17, 2008.
With regard to the declassification of the Aastrom Board of Directors, the report stated: ISS
commends management for submitting this proposal, which demonstrates a commitment to shareholders
interests.*
The report also commented on Aastroms proposal to eliminate the supermajority vote requirement as
follows: ISS maintains that a simple majority of voting shares should be sufficient to effect
changes in a companys corporate governance. Requiring more than a simple majority may permit
management to entrench itself by blocking amendments that are in shareholders best interests.
Therefore, we support the elimination of the supermajority vote requirement and commend the company
for submitting this proposal.*
The Board of Directors of Aastrom unanimously recommends that shareholders vote FOR both of these
proposals which are considered to be good corporate governance practices. These proposals are
described in detail in the fiscal year 2008 Proxy Notice and Statement previously provided to
shareholders of record as of September 2, 2008.
Aastrom and its Board of Directors encourage all shareholders to vote their shares promptly by
phone, Internet, or by mailing their proxy card. If shareholders have any questions or need
assistance in voting their shares, they may contact MacKenzie Partners toll-free at (800) 322-2885
or collect at (212) 929-5500, or Aastroms Investor Relations Department collect at (734) 930-5777.
* Permission to reprint neither requested nor received.
About Aastrom Biosciences, Inc.
Aastrom is a leader in the development of autologous cell products for the repair or regeneration
of human tissue. The Companys proprietary Tissue Repair Cell (TRC) technology involves the use of
a patients own cells to manufacture products to treat a range of chronic diseases and serious
injuries. Aastroms TRC-based products contain increased numbers of stem and early
progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC
technology platform has positioned Aastrom to advance multiple products into clinical development.
Ongoing development activities are focused on applications of the technology to cardiac and
vascular regeneration. The Company currently has a cardiovascular regeneration product in Phase II
development for the treatment of dilated cardiomyopathy (DCM) (called the IMPACT-DCM trial) and
critical limb ischemia (called the RESTORE-CLI trial).
For more information, visit Aastroms website at www.aastrom.com.
This document contains forward-looking statements, including without limitation, statements
concerning planned clinical trials and activities and anticipated timing of clinical events,
product development objectives, and potential product applications, which involve certain risks and
uncertainties. The forward-looking statements are also identified through use of the words
expected, anticipated, planned, and other words of similar meaning. Actual results may
differ significantly from the expectations contained in the forward-looking statements. Among the
factors that may result in differences are potential patient accrual difficulties, clinical trial
results, potential product development difficulties, the effects of competitive therapies,
regulatory approval requirements, the availability of financial and other resources and the
allocation of resources among different potential uses. These and other significant factors are
discussed in greater detail in Aastroms Annual Report on Form 10-K and other filings with the
Securities and Exchange Commission.
###